TerminatedPhase 3NCT06488911
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Intercept Pharmaceuticals
- Principal Investigator
- Lynda Szczech, PhDIntercept Pharmaceuticals Inc.
- Intervention
- FDC tablet (OCA 5 mg + BZF 400 mg SR)(drug)
- Enrollment
- 63 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Southern California Research Center, Coronado, California, United States
- Tampa General Medical Group, Tampa, Florida, United States
- Piedmont Atlanta Hospital, Atlanta, Georgia, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- NYU Langone Health, New York, New York, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Gastro One, Germantown, Tennessee, United States
- East Tennessee Research Institute, Johnson City, Tennessee, United States
- The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
- Houston Methodist Hospital, Houston, Texas, United States
- American Research Corporation, San Antonio, Texas, United States
- DIM Clinica Privada, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06488911 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta